## Drug of Choice for H. influenzae Epiglottitis **Key Point:** Ceftriaxone is the first-line empiric therapy for invasive H. influenzae infections, including epiglottitis, meningitis, and bacteremia, particularly in children. ### Rationale for Ceftriaxone 1. **Broad spectrum coverage** — covers ampicillin-resistant H. influenzae (BLNAR and β-lactamase producers) 2. **Excellent CSF penetration** — critical for meningitis risk in epiglottitis 3. **Rapid bactericidal action** — essential in life-threatening airway disease 4. **High serum and tissue levels** — achieves therapeutic concentrations in all body compartments **High-Yield:** Third-generation cephalosporins (ceftriaxone, cefotaxime) are the standard empiric choice for H. influenzae invasive disease because resistance to amoxicillin is now common (30–40% of strains in India). ### Comparison with Other Options | Drug | Indication | Limitation in Epiglottitis | |------|-----------|---------------------------| | **Ceftriaxone** | First-line, invasive H. influenzae | None — gold standard | | **Amoxicillin** | Susceptible strains only | 30–40% resistance; inadequate for invasive disease | | **TMP-SMX** | Oral step-down, prophylaxis | Poor CSF penetration; not for acute epiglottitis | | **Fluoroquinolone** | Respiratory tract infections | Not first-line in children; reserved for resistant cases | **Clinical Pearl:** Epiglottitis is a medical emergency requiring airway management first, then antibiotics. Ceftriaxone 50–80 mg/kg/day (max 4 g/day) IV is given immediately after blood culture. **Mnemonic:** **CHAMP** (Cephalosporin for H. influenzae Acute Meningitis and epiglottitis Protocol) — remember cephalosporin is the backbone for invasive H. influenzae.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.